Monograph: Arginine, L-

Help on accessing alternative formats, such as Portable document format (PDF), Microsoft word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard. Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion. The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant.
Date: 2018-08-28

NHPID name

L-Arginine ( ChemIDplus Advanced )

Proper name(s)

Common name(s)

L-Arginine ( NIH 2018 , O'Neil et al. 2018 )

Source material

Reference: NIH 2018, BP 2009, USP 32 2009, Ph. Eur. 2007

Route Of administration

Oral

Dosage form(s)

Use(s) or purpose(s)

Statement(s) to the effect of:

Dose(s)

Adults:

Dose(s):

1 Day per day

Duration of use

Risk information

Statement(s) to the effect of:

Caution(s) and Warning(s): Contraindication(s): Doses greater than or equal to 0.42 Grams per day: Do not use this product if you have had a heart attack/myocardial infarction.  (Shulman et al. 2006) Known Adverse Reaction(s): Doses greater than or equal to 0.42 Grams per day: Some people may experience gastrointestinal discomfort (such as diarrhea).  (Grimble 2007, IOM 2005, Evans et al. 2004, Clarkson et al. 1996)

Non-medicinal ingredients

Must be chosen from the current Natural health products ingredients database and must meet the limitations outlined in the database.

Storage conditions

No statement required.

Specifications

References cited

References reviewed

Appendix 1: Examples of appropriate dosage preparations, frequencies of use and directions for use

 

Background information: